409 related articles for article (PubMed ID: 22750078)
1. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
Lipina TV; Palomo V; Gil C; Martinez A; Roder JC
Neuropharmacology; 2013 Jan; 64():205-14. PubMed ID: 22749842
[TBL] [Abstract][Full Text] [Related]
3. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Raheem IT; Breslin MJ; Fandozzi C; Fuerst J; Hill N; Huszar S; Kandebo M; Kim SH; Ma B; McGaughey G; Renger JJ; Schreier JD; Sharma S; Smith S; Uslaner J; Yan Y; Coleman PJ; Cox CD
Bioorg Med Chem Lett; 2012 Sep; 22(18):5903-8. PubMed ID: 22892116
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
5. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
Cannon CE; Puri V; Vivian JA; Egbertson MS; Eddins D; Uslaner JM
Neuropharmacology; 2013 Jan; 64():191-6. PubMed ID: 22659472
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
[TBL] [Abstract][Full Text] [Related]
8. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
[TBL] [Abstract][Full Text] [Related]
10. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.
Vardigan JD; Lange HS; Tye SJ; Fox SV; Smith SM; Uslaner JM
Psychopharmacology (Berl); 2016 Jul; 233(13):2441-50. PubMed ID: 27117142
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
12. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
Suzuki K; Harada A; Shiraishi E; Kimura H
J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
Nakashima M; Imada H; Shiraishi E; Ito Y; Suzuki N; Miyamoto M; Taniguchi T; Iwashita H
J Pharmacol Exp Ther; 2018 Apr; 365(1):179-188. PubMed ID: 29440309
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats.
Takakuwa M; Watanabe Y; Saijo T; Murata M; Anabuki J; Tezuka T; Sato S; Kojima K; Hashimoto K
Pharmacol Biochem Behav; 2020 Sep; 196():172972. PubMed ID: 32562717
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
Hebb AL; Robertson HA; Denovan-Wright EM
Eur Neuropsychopharmacol; 2008 May; 18(5):339-63. PubMed ID: 17913473
[TBL] [Abstract][Full Text] [Related]
17. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
[TBL] [Abstract][Full Text] [Related]
18. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
[TBL] [Abstract][Full Text] [Related]
19. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
[TBL] [Abstract][Full Text] [Related]
20. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
